Oppenheimer Reiterates Outperform Rating on Capricor Therapeutics (CAPR)

October 8, 2026 4:50 AM

Oppenheimer analyst Leland Gershall reiterated an Outperform rating and $54.00 price target on Capricor Therapeutics (NASDAQ: CAPR).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found